Rachael Crist

Dr. Rachael Crist

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
SSStephan Timothy Stern
Stephan Timothy Stern
PAPavan P Adiseshaiah
Pavan P Adiseshaiah
RCRachael Crist
Rachael Crist
The study of the potential risks associated with the manufacture, use, and disposal of nanoscale materials, and their mechanisms of toxicity, is important for the continued advancement of nanotechnology. Currently, the most widely accepted paradigms of nanomaterial toxicity are oxidative stress and inflammation, but the underlying mechanisms are poorly defined. This review will highlight the significance of autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Most endocytic routes of nanomaterial cell uptake converge upon the lysosome, making the lysosomal compartment the most common intracellular site of nanoparticle sequestration and degradation. In addition to the endo-lysosomal pathway, recent evidence suggests that some nanomaterials can also induce autophagy. Among the many physiological functions, the lysosome, by way of the autophagy (macroautophagy) pathway, degrades intracellular pathogens, and damaged organelles and proteins. Thus, autophagy induction by nanoparticles may be an attempt to degrade what is perceived by the cell as foreign or aberrant. While the autophagy and endo-lysosomal pathways have the potential to influence the disposition of nanomaterials, there is also a growing body of literature suggesting that biopersistent nanomaterials can, in turn, negatively impact these pathways. Indeed, there is ample evidence that biopersistent nanomaterials can cause autophagy and lysosomal dysfunctions resulting in toxicological consequences.

31 July 2017 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
MSMackensie C. Smith
Mackensie C. Smith
RCRachael Crist
Rachael Crist
Jeffrey ClogstonJeffrey Clogston
Jeffrey Clogston
SMScott E. McNeil
Scott E. McNeil

6 July 2012 in Integrative Biology
Verified
Journal Article
Closed access
PDF file
RCRachael Crist
Rachael Crist
JGJennifer Hall Grossman
Jennifer Hall Grossman
APAnil K. Patri
Anil K. Patri
SSStephan T. Stern
Stephan T. Stern
MDMarina A. Dobrovolskaia
Marina A. Dobrovolskaia
SMScott E. McNeil
Scott E. McNeil
The NCL discusses many of the complexities associated with nanoparticle synthesis, purification, characterization and analysis.

17 August 2016 in Nature Reviews Clinical Oncology
Verified
Journal Article
Open access
PDF file
PAPavan P. Adiseshaiah
Pavan P. Adiseshaiah
RCRachael Crist
Rachael Crist
SHSara S. Hook
Sara S. Hook
SMScott E. McNeil
Scott E. McNeil
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer- related deaths. PDAC remains one of the most difficult-to-treat cancers, owing to its unique pathobiological features: a nearly impenetrable desmoplastic stroma, and hypovascular and hypoperfused tumour vessels render most treatment options largely ineffective. Progress in understanding the pathobiology and signalling pathways involved in disease progression is helping researchers to develop novel ways to fight PDAC, including improved nanotechnology-based drug-delivery platforms that have the potential to overcome the biological barriers of the disease that underlie persistent drug resistance. So-called 'nanomedicine' strategies have the potential to enable targeting of the Hedgehog-signalling pathway, the autophagy pathway, and specific RAS-mutant phenotypes, among other pathological processes of the disease. These novel therapies, alone or in combination with agents designed to disrupt the pathobiological barriers of the disease, could result in superior treatments, with increased efficacy and reduced off-target toxicities compared with the current standard-of-care regimens. By overcoming drug-delivery challenges, advances can be made in the treatment of PDAC, a disease for which limited improvement in overall survival has been achieved over the past several decades. We discuss the approaches to nanomedicine that have been pursued to date and those that are the focus of ongoing research, and outline their potential, as well as the key challenges that must be overcome.

3 July 2019 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
HLHon S. Leong
Hon S. Leong
KBKimberly S. Butler
Kimberly S. Butler
CBC. Jeffrey Brinker
C. Jeffrey Brinker
MAMay Azzawi
May Azzawi
SCSteve Conlan
Steve Conlan
CPChiara Pastore
Chiara Pastore

26 October 2006 in Journal of Molecular Biology
Verified
Journal Article
Closed access
SDSiddhartha Datta
Siddhartha Datta
JCJoseph E. Curtis
Joseph E. Curtis
WRWilliam Ratcliff
William Ratcliff
PCPatrick K. Clark
Patrick K. Clark
RCRachael Crist
Rachael Crist
ARAlan Rein
Alan Rein